News

AstraZeneca buys Md.-based biotech firm

BY Alaric DeArment

LONDON — AstraZeneca has bought Maryland-based biotech company Amplimmune, the drug maker said.

AstraZeneca announced the acquisition of privately owned Amplimmune through its MedImmune biologics research and development subsidiary, saying it would boost its cancer drug pipeline. Amplimmune’s pipeline includes several experimental treatments, such as AMP-514, a monoclonal antibody currently in preclinical development for which the company hopes to apply to start clinical trials before the end of the year.

"MedImmune’s focus on harnessing the power of the patient’s own immune system to fight cancer will be complemented by Amplimmune’s innovative work in this area," MedImmune EVP Bahija Jallal said. "It will allow us to strengthen our arsenal of potential cancer therapies."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Consumers are shopping smarter across BTS

BY Michael Johnsen

More than half of viewers indicated they will seek out sales more than they have in past years, according to an online survey of more than 500 AccentHealth viewers conducted in July. As many as 26% reported they would spend more this year, while 1-in-5 plan to buy more preventive products. To see more Patient Views, click here

Patient Views is an exclusive consumer insights feature that appears regularly in DSN magazine, as well as the daily e-newsletter DSN A.M. If you could ask more than 6,000 patients anything at all, what would it be? Send your questions to [email protected].

Source: AccentHealth. To view the demographic breakdown of participants, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Coupons drive BTS consumers into atypical channels

BY Michael Johnsen

As many as 90% of viewers indicated coupons or savings would incentivize them to purchase back-to-school products at a new store, according to an online survey of more than 500 AccentHealth viewers conducted in July. And 66% are likely to purchase back to school merchandise at a retail pharmacy in the future — up from 38% of current purchasers. To see more Patient Views, click here.

Patient Views is an exclusive consumer insights feature that appears regularly in DSN magazine, as well as the daily e-newsletter DSN A.M. If you could ask more than 6,000 patients anything at all, what would it be? Send your questions to [email protected].

Source: AccentHealth. To view the demographic breakdown of participants, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES